Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Skyhawk expands drug discovery with Merck
by Ryan Cross
May 15, 2020
| A version of this story appeared in
Volume 98, Issue 19
Merck & Co. has expanded its collaboration with Skyhawk Therapeutics to develop small-molecule drugs that modify RNA splicing in autoimmune and metabolic diseases. The deal builds on an agreement the firms announced last summer to develop drugs for neurodegenerative diseases and cancer. Skyhawk will get an undisclosed up-front payment and could receive up to $600 million per drug program. Skyhawk, which was one of C&EN’s 10 Start-Ups to Watch in 2019, also has collaborations with Biogen, Celgene, and Takeda Pharmaceutical.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter